Emiliano Tamburini

Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarc...

Lancet (London, England) · 20 december 2026

Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 februari 2026

The relative dose intensity of eerstelijns FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects ...

European journal of cancer (Oxford, England : 1990) · 3 juni 2025

Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for Eerstelijns Behandeling of R...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025-03

FOLFOXIRI-bev met of zonder atezolizumab bij gemetastaseerd CRC: AtezoTRIBE langetermijn

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 augustus 2024

Immuun-gensignatuur en atezolizumab-voordeel bij FOLFOXIRI-bev bij CRC: AtezoTRIBE analyse

Clinical cancer research : an official journal of the American Association for Cancer Research · 13 juni 2023

Atezo-bev versus lenvatinib bij HCC: retrospectieve vergelijking

European journal of cancer (Oxford, England : 1990) · 2023-02

mFOLFOXIRI plus panitumumab versus FOLFOX plus panitumumab bij RAS/BRAF-wildtype CRC: VOLFI fase II

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 september 2022

FOLFOXIRI-bevacizumab met of zonder atezolizumab bij gemetastaseerd CRC: AtezoTRIBE fase II

The Lancet. Oncology · 2022-07

Oligometastatisch CRC: prognose en locoregionale behandeling

European journal of cancer (Oxford, England : 1990) · 2020-11

Upfront FOLFOXIRI-bevacizumab en herintroductie versus mFOLFOX6-bevacizumab bij CRC: TRIBE-2 fase III

The Lancet. Oncology · 2020-04

Publicaties op Oncologisch.com